Stockreport

uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF Syndax (SNDX) raised to $45, trades at $23.23, Q4 revenue $44.20M up 38%; Erasca (ERAS) gets $24 target, up 305.17% YTD. uniQure's FDA regulatory path improves after V [Read more]